BMO Capital analyst Alex Arfaei assigned a Buy rating to AstraZeneca (NYSE: AZN) today and set a price target of $41. The company’s shares closed yesterday at $36.38, close to its 52-week high of $37.30.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 5.0% and a 66.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
AstraZeneca has an analyst consensus of Moderate Buy, with a price target consensus of $41.
See today’s analyst top recommended stocks >>
Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $342 million. In comparison, last year the company had a net profit of $542 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.
